{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-061146","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.388582+00:00","generated_at":"2026-06-02T00:17:22.818707+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cyclacel reports Q1 net loss of $2.9M; begins Phase 2 fadraciclib enrollment; secures $8M private placement","bullets":["Net loss of $2.9M for Q1 2024 compared to $5.8M in Q1 2023; R&D expenses fell to $2.8M from $5.7M.","Pro forma cash $9.9M including $8M private placement proceeds; actual cash $2.8M at March 31, 2024.","Phase 2 proof-of-concept study for oral fadraciclib enrolling patients; final Phase 1 data to be presented at ASCO 2024.","$8.0 million private placement completed under Nasdaq rules, bolstering balance sheet.","Net cash used in operations was $0.5M in Q1 2024 vs $6.9M in Q1 2023; company expects funding into Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-061146","json":"https://secwatch.observer/filing/0001104659-24-061146.json","markdown":"https://secwatch.observer/filing/0001104659-24-061146.md","text":"https://secwatch.observer/filing/0001104659-24-061146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465924061146/0001104659-24-061146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465924061146/tm2414455d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:17:22.818707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2903b8b72f2999ab4c71b68fdc89b50410455228","claim":"Bio Green Med Solution, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the three months March 31, 2024, was $2.9 million (including stock-based compensation expense of $0.2 milli.","evidence_excerpt":"Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; \"Cyclacel\" or the \"Company\"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today first quarter financial results and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465924061146/0001104659-24-061146-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the three months March 31, 2024, was $2.9 million (including stock-based compensation expense of $0.2 milli"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}